Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
Palle Bekker Jeppesen; Richard Gilroy; M. Pertkiewicz; Johane P. Allard; Bernard Messing; Stephen J. O’Keefe · 2011 · Gut
WASTE classifies this as Replication Failure · AI classification, approximate
A previously reported effect did not replicate here — verify it holds before you build on it.
Abstract (excerpt)
BACKGROUND AND AIMS: Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient…
Excerpt shown for reference under fair use — read the full paper at the publisher.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Negative / Null Result ReportAgricultural commercialization and nutrition revisited: Empirical evidence from three African countries
Negative / Null Result ReportEffect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders
Negative / Null Result ReportThe diversity and function of sourdough starter microbiomes
Replication FailureSelenium supplementation for the primary prevention of cardiovascular disease
Negative / Null Result ReportDaily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1136/gut.2010.218271